ICCC Immucell Corp
Price (delayed)
$5.5
Market cap
$49.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$60.75M
ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate
Highlights
ICCC's quick ratio has surged by 128% year-on-year and by 25% since the previous quarter
ICCC's gross profit has soared by 105% YoY and by 25% QoQ
Key stats
What are the main financial stats of ICCC
Market
Valuations
Earnings
Shares outstanding
8.98M
Market cap
$49.4M
Enterprise value
$60.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.78
Price to sales (P/S)
1.7
EV/EBIT
N/A
EV/EBITDA
112.37
EV/Sales
2.29
Revenue
$26.49M
Gross profit
$7.94M
Operating income
-$1.64M
Net income
-$2.16M
EBIT
-$2.15M
EBITDA
$540,608
Free cash flow
-$103,322
Per share
Balance sheet
Liquidity
EPS
-$0.26
EPS diluted
-$0.26
Free cash flow per share
-$0.01
Book value per share
$3.09
Revenue per share
$3.24
TBVPS
$5.51
Total assets
$45.1M
Total liabilities
$17.58M
Debt
$15.1M
Equity
$27.52M
Working capital
$10.63M
Debt to equity
0.55
Current ratio
3.41
Quick ratio
1.71
Net debt/EBITDA
20.98
Margins
Efficiency
Dividend
EBITDA margin
2%
Gross margin
30%
Net margin
-8.1%
Operating margin
-6.2%
Return on assets
-4.9%
Return on equity
-8.5%
Return on invested capital
-4.1%
Return on capital employed
-5.3%
Return on sales
-8.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ICCC stock price
How has the Immucell stock price performed over time
Intraday
0.18%
1 week
8.59%
1 month
10.66%
1 year
8.91%
YTD
6.8%
QTD
14.82%
Financial performance
How have Immucell's revenue and profit performed over time
Revenue
$26.49M
Gross profit
$7.94M
Operating income
-$1.64M
Net income
-$2.16M
Gross margin
30%
Net margin
-8.1%
ICCC's gross profit has soared by 105% YoY and by 25% QoQ
The operating margin has surged by 81% year-on-year and by 55% since the previous quarter
Immucell's net margin has soared by 76% YoY and by 49% from the previous quarter
The operating income has soared by 71% year-on-year and by 50% since the previous quarter
Growth
What is Immucell's growth rate over time
Valuation
What is Immucell stock price valuation
P/E
N/A
P/B
1.78
P/S
1.7
EV/EBIT
N/A
EV/EBITDA
112.37
EV/Sales
2.29
ICCC's EPS has surged by 65% year-on-year and by 48% since the previous quarter
The stock's P/B is 19% more than its last 4 quarters average of 1.5 and 4.7% more than its 5-year quarterly average of 1.7
The company's equity rose by 10% YoY and by 4.2% QoQ
Immucell's revenue has surged by 52% YoY and by 11% QoQ
The stock's P/S is 39% less than its 5-year quarterly average of 2.8 but 6% more than its last 4 quarters average of 1.6
Efficiency
How efficient is Immucell business performance
ICCC's return on sales has surged by 75% year-on-year and by 49% since the previous quarter
The ROA has soared by 63% year-on-year and by 44% since the previous quarter
ICCC's ROIC has soared by 62% year-on-year and by 43% since the previous quarter
The company's return on equity has surged by 61% YoY and by 44% QoQ
Dividends
What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ICCC.
Financial health
How did Immucell financials performed over time
ICCC's total assets is 157% higher than its total liabilities
ICCC's quick ratio has surged by 128% year-on-year and by 25% since the previous quarter
Immucell's current ratio has increased by 25% YoY and by 10% from the previous quarter
Immucell's debt is 45% less than its equity
The company's debt to equity fell by 18% YoY and by 7% QoQ
Immucell's debt has decreased by 10% YoY and by 2.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.